CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
erlotinib [Tarceva]drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02013206
NCT02013206Phase 2Completed
CompareCT.gov

An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current and Former Smokers

Hoffmann-La Roche·interventional·Posted Dec 17, 2013·Updated Dec 19, 2014

In Brief

A Phase 2 clinical trial evaluating erlotinib [Tarceva] for Non-Small Cell Lung Cancer. Completed, enrolled 52 participants across 11 sites in 6 countries.

Detailed Summary

This study will evaluate the efficacy and safety of Tarceva in two groups of patients with non-small cell lung cancer who have not been pre-treated with chemotherapy. One group, consisting of patients who have never smoked, will receive Tarceva 150 mg/day, and the other group, consisting of current/former smokers, will receive Tarceva 150 mg/day increasing to a maximum of 300 mg/day. The anticipated time on study treatment is 1-2 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesFrance, Germany, Italy, Netherlands, Spain, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 17, 2013
Enrollment StartSep 1, 2006
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.5 years ago

Interventions

erlotinib [Tarceva]drug

Erlotinib tablets taken orally once daily in the morning.